Anat Loewenstein, EURETINA 2022: Home Monitoring for Age-related Macular Degeneration
It was a pleasure to interview Prof. Anat Loewenstein (Tel Aviv Medical Center, Tel Aviv, Israel) on her EURETINA presentation discussing the advantages of home monitoring of age-related macular degeneration, and the results of a study evaluating a new device for home monitoring.
The abstract ‘Functional and anatomical options for home monitoring in the era of long duration treatments for AMD’ was presented at EURETINA 2022, 1–4 September 2022
- What are the advantages of home rather than in-office monitoring of age-related macular degeneration? (00:21)
- Could you tell us a little about the home monitoring device you have evaluated? (01:03)
- What were the design and outcome measures of your pilot study? (01:58)
- What were the study findings? (03:38)
- What questions remain unanswered about these devices, and what future studies are planned? (04:24)
Disclosure: Anat Loewenstein is a consultant for Roche, Novartis, NotalVision, Bayer and Beyeonics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of EURETINA 2022.
Share this Video
Related Videos In Macular Degeneration
Jordana Fein, ARVO 2023: Phase II CANDELA study post hoc analysis: intravitreal aflibercept injection 8 mg versus 2 mg
The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure to speak with Dr Jordana Fein (Retina Group of Washington Fairfax, VA, USA) […]
Jordana Fein, ARVO 2023: Current therapeutic options for neovascular age-related macular degeneration
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. It was […]
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!